Ben Turner

About

Staff Writer Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.
51 POSTS

/

0 COMMENTS

Articles

Dogs or mice? Our exclusive with Dr Steven Austad

If we're going to find robust solutions for aging, we may need more than mouse models — argues the University of Alabama at Birmingham's...

Zealand Pharma bets bigger on peptides

The Copenhagen biotech's acquisition of Encycle Therapeutics demonstrates growing market interest in peptide-based drugs. Zealand Pharma, a Copenhagen-based biotech company focused on the development of...

Closed-loop pancreas system aces trial

Tandem and Dexcom system aces closed-loop pancreas trial for type 1 diabetes, but doesn't appear to break new ground over existing market competitor. A clinical...

Bayer backs 11 digital health and AI startups

Pharma giant Bayer is pursuing ambitious collaborations with Longevity-based companies, but Roundup pressure continues to mount. Bayer AG, the multinational pharmaceutical and life sciences company,...

Deep dive report: From mice to men

Mouse models used for research in aging therapies can only go so far in progressing human Longevity. Longevity.Technology: In this deep dive report we talk with experienced...

AI biomarker built to measure brain age

University of Oslo researchers develop AI biomarker for tracking neurological treatment over time. Finding timely therapies for age begins with finding a way to measure...

4Gen Ventures announces 2020 launch date

New Age-tech fund will capitalise upon trend towards “multi-generational living" 4Gen Ventures, a new venture capital fund entering the Agetech space, plans to begin investing...

Forever Young – our exclusive with Sergey Young

As the longevity investor's new fund turns 8 months old this month, we went five for five with Sergey Young. Longevity.Technology: We often find people...

Exclusive Profile: The Buck Institute’s Eric Verdin

The best funded Buck Institute for aging research celebrates its 20th birthday, and tells us its plans for the next 20. For the scientists old...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.